@article{ElSahlyHanaM2021Eotm,
abstract = {The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.},
author = {El Sahly, Hana M and Baden, Lindsey R and Essink, Brandon and Doblecki-Lewis, Susanne and Martin, Judith M and Anderson, Evan J and Campbell, Thomas B and Clark, Jesse and Jackson, Lisa A and Fichtenbaum, Carl J and Zervos, Marcus and Rankin, Bruce and Eder, Frank and Feldman, Gregory and Kennelly, Christina and Han-Conrad, Laurie and Levin, Michael and Neuzil, Kathleen M and Corey, Lawrence and Gilbert, Peter and Janes, Holly and Follmann, Dean and Marovich, Mary and Polakowski, Laura and Mascola, John R and Ledgerwood, Julie E and Graham, Barney S and August, Allison and Clouting, Heather and Deng, Weiping and Han, Shu and Leav, Brett and Manzo, Deb and Pajon, Rolando and Schödel, Florian and Tomassini, Joanne E and Zhou, Honghong and Miller, Jacqueline},
address = {United States},
copyright = {Copyright © 2021 Massachusetts Medical Society. All rights reserved.},
issn = {0028-4793},
journal = {The New England journal of medicine},
keywords = {2019-nCoV Vaccine mRNA-1273 ; Adolescent ; Adult ; Aged ; Asymptomatic ; Asymptomatic infection ; Clinical trials ; Consent ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Follow-Up Studies ; Humans ; Hypersensitivity ; Immunization ; Immunization, Secondary ; Immunogenicity, Vaccine ; Incidence ; Infections ; Infectious Disease ; Infectious diseases ; Injection ; Injections ; Intention to Treat Analysis ; Male ; Middle Aged ; mRNA ; Original ; Patient Acuity ; Placebos ; Population ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Single-Blind Method ; Statistical analysis ; Treatment Outcome ; Vaccine efficacy ; Vaccines ; Young Adult},
language = {eng},
number = {19},
organization = {COVE Study Group},
pages = {1774-1785},
publisher = {Massachusetts Medical Society},
title = {Efficacy of the {mRNA-1273 SARS-CoV-2} Vaccine at Completion of Blinded Phase},
volume = {385},
year = {2021},
}

{"_id":"eo8Jq4DmdmR7H5HSJ","bibbaseid":"elsahly-baden-essink-dobleckilewis-martin-anderson-campbell-clark-etal-efficacyofthemrna1273sarscov2vaccineatcompletionofblindedphase-2021","author_short":["El Sahly, H. M","Baden, L. R","Essink, B.","Doblecki-Lewis, S.","Martin, J. M","Anderson, E. J","Campbell, T. B","Clark, J.","Jackson, L. A","Fichtenbaum, C. J","Zervos, M.","Rankin, B.","Eder, F.","Feldman, G.","Kennelly, C.","Han-Conrad, L.","Levin, M.","Neuzil, K. M","Corey, L.","Gilbert, P.","Janes, H.","Follmann, D.","Marovich, M.","Polakowski, L.","Mascola, J. R","Ledgerwood, J. E","Graham, B. S","August, A.","Clouting, H.","Deng, W.","Han, S.","Leav, B.","Manzo, D.","Pajon, R.","Schödel, F.","Tomassini, J. E","Zhou, H.","Miller, J."],"bibdata":{"bibtype":"article","type":"article","abstract":"The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.","author":[{"propositions":[],"lastnames":["El","Sahly"],"firstnames":["Hana","M"],"suffixes":[]},{"propositions":[],"lastnames":["Baden"],"firstnames":["Lindsey","R"],"suffixes":[]},{"propositions":[],"lastnames":["Essink"],"firstnames":["Brandon"],"suffixes":[]},{"propositions":[],"lastnames":["Doblecki-Lewis"],"firstnames":["Susanne"],"suffixes":[]},{"propositions":[],"lastnames":["Martin"],"firstnames":["Judith","M"],"suffixes":[]},{"propositions":[],"lastnames":["Anderson"],"firstnames":["Evan","J"],"suffixes":[]},{"propositions":[],"lastnames":["Campbell"],"firstnames":["Thomas","B"],"suffixes":[]},{"propositions":[],"lastnames":["Clark"],"firstnames":["Jesse"],"suffixes":[]},{"propositions":[],"lastnames":["Jackson"],"firstnames":["Lisa","A"],"suffixes":[]},{"propositions":[],"lastnames":["Fichtenbaum"],"firstnames":["Carl","J"],"suffixes":[]},{"propositions":[],"lastnames":["Zervos"],"firstnames":["Marcus"],"suffixes":[]},{"propositions":[],"lastnames":["Rankin"],"firstnames":["Bruce"],"suffixes":[]},{"propositions":[],"lastnames":["Eder"],"firstnames":["Frank"],"suffixes":[]},{"propositions":[],"lastnames":["Feldman"],"firstnames":["Gregory"],"suffixes":[]},{"propositions":[],"lastnames":["Kennelly"],"firstnames":["Christina"],"suffixes":[]},{"propositions":[],"lastnames":["Han-Conrad"],"firstnames":["Laurie"],"suffixes":[]},{"propositions":[],"lastnames":["Levin"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Neuzil"],"firstnames":["Kathleen","M"],"suffixes":[]},{"propositions":[],"lastnames":["Corey"],"firstnames":["Lawrence"],"suffixes":[]},{"propositions":[],"lastnames":["Gilbert"],"firstnames":["Peter"],"suffixes":[]},{"propositions":[],"lastnames":["Janes"],"firstnames":["Holly"],"suffixes":[]},{"propositions":[],"lastnames":["Follmann"],"firstnames":["Dean"],"suffixes":[]},{"propositions":[],"lastnames":["Marovich"],"firstnames":["Mary"],"suffixes":[]},{"propositions":[],"lastnames":["Polakowski"],"firstnames":["Laura"],"suffixes":[]},{"propositions":[],"lastnames":["Mascola"],"firstnames":["John","R"],"suffixes":[]},{"propositions":[],"lastnames":["Ledgerwood"],"firstnames":["Julie","E"],"suffixes":[]},{"propositions":[],"lastnames":["Graham"],"firstnames":["Barney","S"],"suffixes":[]},{"propositions":[],"lastnames":["August"],"firstnames":["Allison"],"suffixes":[]},{"propositions":[],"lastnames":["Clouting"],"firstnames":["Heather"],"suffixes":[]},{"propositions":[],"lastnames":["Deng"],"firstnames":["Weiping"],"suffixes":[]},{"propositions":[],"lastnames":["Han"],"firstnames":["Shu"],"suffixes":[]},{"propositions":[],"lastnames":["Leav"],"firstnames":["Brett"],"suffixes":[]},{"propositions":[],"lastnames":["Manzo"],"firstnames":["Deb"],"suffixes":[]},{"propositions":[],"lastnames":["Pajon"],"firstnames":["Rolando"],"suffixes":[]},{"propositions":[],"lastnames":["Schödel"],"firstnames":["Florian"],"suffixes":[]},{"propositions":[],"lastnames":["Tomassini"],"firstnames":["Joanne","E"],"suffixes":[]},{"propositions":[],"lastnames":["Zhou"],"firstnames":["Honghong"],"suffixes":[]},{"propositions":[],"lastnames":["Miller"],"firstnames":["Jacqueline"],"suffixes":[]}],"address":"United States","copyright":"Copyright © 2021 Massachusetts Medical Society. All rights reserved.","issn":"0028-4793","journal":"The New England journal of medicine","keywords":"2019-nCoV Vaccine mRNA-1273 ; Adolescent ; Adult ; Aged ; Asymptomatic ; Asymptomatic infection ; Clinical trials ; Consent ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Follow-Up Studies ; Humans ; Hypersensitivity ; Immunization ; Immunization, Secondary ; Immunogenicity, Vaccine ; Incidence ; Infections ; Infectious Disease ; Infectious diseases ; Injection ; Injections ; Intention to Treat Analysis ; Male ; Middle Aged ; mRNA ; Original ; Patient Acuity ; Placebos ; Population ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Single-Blind Method ; Statistical analysis ; Treatment Outcome ; Vaccine efficacy ; Vaccines ; Young Adult","language":"eng","number":"19","organization":"COVE Study Group","pages":"1774-1785","publisher":"Massachusetts Medical Society","title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","volume":"385","year":"2021","bibtex":"@article{ElSahlyHanaM2021Eotm,\nabstract = {The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.},\nauthor = {El Sahly, Hana M and Baden, Lindsey R and Essink, Brandon and Doblecki-Lewis, Susanne and Martin, Judith M and Anderson, Evan J and Campbell, Thomas B and Clark, Jesse and Jackson, Lisa A and Fichtenbaum, Carl J and Zervos, Marcus and Rankin, Bruce and Eder, Frank and Feldman, Gregory and Kennelly, Christina and Han-Conrad, Laurie and Levin, Michael and Neuzil, Kathleen M and Corey, Lawrence and Gilbert, Peter and Janes, Holly and Follmann, Dean and Marovich, Mary and Polakowski, Laura and Mascola, John R and Ledgerwood, Julie E and Graham, Barney S and August, Allison and Clouting, Heather and Deng, Weiping and Han, Shu and Leav, Brett and Manzo, Deb and Pajon, Rolando and Schödel, Florian and Tomassini, Joanne E and Zhou, Honghong and Miller, Jacqueline},\naddress = {United States},\ncopyright = {Copyright © 2021 Massachusetts Medical Society. All rights reserved.},\nissn = {0028-4793},\njournal = {The New England journal of medicine},\nkeywords = {2019-nCoV Vaccine mRNA-1273 ; Adolescent ; Adult ; Aged ; Asymptomatic ; Asymptomatic infection ; Clinical trials ; Consent ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Follow-Up Studies ; Humans ; Hypersensitivity ; Immunization ; Immunization, Secondary ; Immunogenicity, Vaccine ; Incidence ; Infections ; Infectious Disease ; Infectious diseases ; Injection ; Injections ; Intention to Treat Analysis ; Male ; Middle Aged ; mRNA ; Original ; Patient Acuity ; Placebos ; Population ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Single-Blind Method ; Statistical analysis ; Treatment Outcome ; Vaccine efficacy ; Vaccines ; Young Adult},\nlanguage = {eng},\nnumber = {19},\norganization = {COVE Study Group},\npages = {1774-1785},\npublisher = {Massachusetts Medical Society},\ntitle = {Efficacy of the {mRNA-1273 SARS-CoV-2} Vaccine at Completion of Blinded Phase},\nvolume = {385},\nyear = {2021},\n}\n\n","author_short":["El Sahly, H. M","Baden, L. R","Essink, B.","Doblecki-Lewis, S.","Martin, J. M","Anderson, E. J","Campbell, T. B","Clark, J.","Jackson, L. A","Fichtenbaum, C. J","Zervos, M.","Rankin, B.","Eder, F.","Feldman, G.","Kennelly, C.","Han-Conrad, L.","Levin, M.","Neuzil, K. M","Corey, L.","Gilbert, P.","Janes, H.","Follmann, D.","Marovich, M.","Polakowski, L.","Mascola, J. R","Ledgerwood, J. E","Graham, B. S","August, A.","Clouting, H.","Deng, W.","Han, S.","Leav, B.","Manzo, D.","Pajon, R.","Schödel, F.","Tomassini, J. E","Zhou, H.","Miller, J."],"key":"ElSahlyHanaM2021Eotm","id":"ElSahlyHanaM2021Eotm","bibbaseid":"elsahly-baden-essink-dobleckilewis-martin-anderson-campbell-clark-etal-efficacyofthemrna1273sarscov2vaccineatcompletionofblindedphase-2021","role":"author","urls":{},"keyword":["2019-nCoV Vaccine mRNA-1273 ; Adolescent ; Adult ; Aged ; Asymptomatic ; Asymptomatic infection ; Clinical trials ; Consent ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Follow-Up Studies ; Humans ; Hypersensitivity ; Immunization ; Immunization","Secondary ; Immunogenicity","Vaccine ; Incidence ; Infections ; Infectious Disease ; Infectious diseases ; Injection ; Injections ; Intention to Treat Analysis ; Male ; Middle Aged ; mRNA ; Original ; Patient Acuity ; Placebos ; Population ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Single-Blind Method ; Statistical analysis ; Treatment Outcome ; Vaccine efficacy ; Vaccines ; Young Adult"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/ayLmL7LfP6KeTgPMB/Missing-Cause-COVID.bib","dataSources":["yH4vGG8Z2YfEaPgTe"],"keywords":["2019-ncov vaccine mrna-1273 ; adolescent ; adult ; aged ; asymptomatic ; asymptomatic infection ; clinical trials ; consent ; coronavirus ; coronaviruses ; covid-19 ; covid-19 - epidemiology ; covid-19 - prevention & control ; covid-19 vaccines ; covid-19 vaccines - adverse effects ; covid-19 vaccines - immunology ; follow-up studies ; humans ; hypersensitivity ; immunization ; immunization","secondary ; immunogenicity","vaccine ; incidence ; infections ; infectious disease ; infectious diseases ; injection ; injections ; intention to treat analysis ; male ; middle aged ; mrna ; original ; patient acuity ; placebos ; population ; safety ; severe acute respiratory syndrome coronavirus 2 ; single-blind method ; statistical analysis ; treatment outcome ; vaccine efficacy ; vaccines ; young adult"],"search_terms":["efficacy","mrna","1273","sars","cov","vaccine","completion","blinded","phase","el sahly","baden","essink","doblecki-lewis","martin","anderson","campbell","clark","jackson","fichtenbaum","zervos","rankin","eder","feldman","kennelly","han-conrad","levin","neuzil","corey","gilbert","janes","follmann","marovich","polakowski","mascola","ledgerwood","graham","august","clouting","deng","han","leav","manzo","pajon","schödel","tomassini","zhou","miller"],"title":"Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase","year":2021}